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ABSTRACT 
Traditional functional assays such as hemagglutination inhibition (HAI) and micro-
neutralization (MN) assays have been routinely used for assessing the vaccine response, since 
influenza vaccine has been administered in people (1940). Such assays are not always predictive 
regarding the protection conferred by the influenza vaccine and are not able to monitor 
neutralization related to stem region of influenza hemagglutinin responsible for virus membrane 
fusion in the endosomes.  In order to study Influenza vaccine response in a more biomimetic 
manner and overcome the deficiencies of the traditional functional assays, we developed a 
fluorescent membrane fusion assay (fMF). The assay uses viruses labeled with Octadecyl 
Rhodmaine B Chloride (R18) to monitor two major neutralization pathways: blocking the 
attachment of virus to the target cells and blocking of virus membrane fusion in the endosomes. 
The latter was tested using endosomal acidification inhibitor Bafilomycin a1 which blocked 
membrane fusion by 85%. Specificity of the assay was tested using two different subtypes of 
viruses H1N1 (A/Puerto Rico/8/1934 and A/Brisbane/59/2007), and H3N2 virus (A/Aichi/68) 
with their respective subtype specific stem specific monoclonal antibodies: M145, Aca-1, Aca-2 
(H1N1 specific) and Aca-3 (H3N2 specific). Subtype specific mAbs blocked membrane fusion, 
while a mismatch in virus subtype and the mAb resulted in lack of blocking. We also studied the 
effect of H1N1 head specific mAb Aca-4, which not only blocked attachment of the virus, but 
also demonstrated blocking of membrane fusion. Results were validated by testing pre- and post- 
sera from 2009 seasonal Influenza vaccination and to show that at higher Ab concentration the 
majority of virus (85%) was blocked from attaching cells, but at lower Ab concentration, where 
attachment could not be prevented, blocking of membrane fusion was still in effect - up to 50%. 
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Sera screening experiments showed that sera antibodies work beyond just blocking attachment. 
They also may neutralize the already attached virus by blocking fusion of the viral membrane in 
the endosomes. The assay has the capacity to monitor blocking of attachment and fusion in a 
single run. Therefore, it is more representative regarding the natural process of infection and the 
corresponding neutralization pathways. The assay is unique in terms of assessing stem specific 
antibodies; stem specific response and its measurement are relevant for the advancement of a 
universal influenza vaccine. 
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INTRODUCTION 
Influenza is a respiratory disease caused by influenza virus. The virus causes seasonal 
outbreaks every year and pandemics are caused sporadically. The burden of disease is 
tremendous, worldwide every year there are hundreds of millions of influenza cases, with 3 to 5 
million cases of severe illnesses and 250,000 to 500,000 people die from the illness[1]. The 
disease readily attacks and spreads easily in immunocompromised individuals such as older 
population, younger children and people with ongoing medical conditions[2]. 
Influenza vaccine is the most widespread method of protection against influenza virus. 
Inactivated seasonal Influenza vaccines came into practice in 1940’s followed by live attenuated 
influenza vaccine in 1960’s[3]. The response to the vaccine is mounted in form of serum 
antibodies. These antibodies are directed mainly towards the globular head of virus’s surface 
glycoprotein Hemagglutinin (HA). In order to escape the immune response of its host, the virus 
frequently mutates epitopes on the head region of its HA[4]. For this reason, influenza vaccines 
need to be reformulated every year, based on the currently circulating strain recommendations 
made by WHO’s influenza surveillance programs[5]. This approach to formulating vaccines is 
very well established and saves human lives and resources every year. On the other hand, this 
process of influenza vaccine production costs $1-2 billion every year. In addition to the high cost 
associated with yearly vaccine reformulation, pandemic strains are unexpected, difficult to 
predict, and seasonal strain matching with vaccine is not always accurate[6]. In the wake of these 
issues, the influenza vaccines portfolio is evolving.  
There have been many new advances made to existing influenza vaccine such as using 
higher dose of HA to generate a better antibody response for elderly population. Recently, 
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quadrivalent flu vaccine was approved to provide broader protection as it contains two A strains 
(H1N1 and H3N2) and two B strains, to cover both most probably expected B lineages in the 
vaccine. In addition, modifications such as intradermal vaccine, using oil in water emulsion 
adjuvant have also been made to existing licensed vaccine[7]. In order to alleviate the need for 
reformulating vaccine every year, current scientific efforts are enthusiastically directed towards 
development of a Universal influenza vaccine. The universal vaccine approach is based on 
targeting conserved epitopes on influenza virus proteins such as stem region of HA, 
nucleoprotein and M2 channel protein[8].  
The serum antibody response towards globular head of HA is accepted as primary 
correlate of protection for influenza vaccine. This antihead response is universally tested by 
hemagglutination inhibition (HI, or HAI) assay. HI assay is based upon agglutinating ability of 
influenza virus towards red blood cells. In presence of HA head specific antibodies the 
agglutination of RBCs by influenza virus is inhibited. An HI titer 40 is generally recognized as 
measure of 50% protection[9]. With the evolving influenza vaccine portfolio the correlates of 
protection are changing[7]. For example, with universal flu vaccine being based mainly on stem 
region of HA, measuring stem specific response is becoming crucial and the stem specific 
response has become a new correlate of protection. 
The HA protein on influenza virus is a trimeric molecule consisting of three identical HA 
molecules. The protein appears as spikes on the surface of influenza virus envelope. The HA 
spike is divided into three domains: globular head responsible for virus attachment to host cells, 
stem domain which is responsible for membrane fusion in endosomes of host cells and a 
transmembrane domain which holds the  HA trimer into viral membrane[10]. The globular head 
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is the most antigenic and variable region. The epitopes on head are 98% variable among different 
subtypes and strains of influenza virus. On the other hand, the stem region has epitopes which 
are more than 98% conserved amongst different influenza viruses. The highly conserved 
structure of HA stem amongst various subtypes of influenza virus make it a very attractive target 
for developing universal flu vaccine[6]. Scientists have shown that natural infection and seasonal 
vaccine are able to generate stem specific antibodies in humans. Many stem specific monoclonal 
antibodies (mAbs) have been isolated from humans that are able to neutralize a wide range of 
influenza viruses of different subtypes and strains[11-13]. Now the efforts are being made to 
boost up the stem specific antibody response after vaccination. Approaches towards such 
vaccines include stem based vaccine constructs without globular head[14] and chimeric 
hemagglutinin based vaccine constructs[15]. There are studies that have shown that stem based 
vaccine constructs are able to generate heterosubtypic neutralizing antibodies in animal 
studies[15, 16]. Although there is a definitive amount of progress that has been made in direction 
of stem based vaccines, still there are few substantive methods to assess general anti-virus 
immune response, and no universally accepted laboratory methods that can be used to measure 
stem specific response. Therefore, there is need to develop a method that can measure this new 
correlate of protection i.e., functional effect of stem specific antibodies. 
On another note, a study in neonatal pigs showed that mismatch between vaccine and 
infecting virus has been reported to generate stem specific antibodies that increase endosomal 
membrane fusion, thereby increasing the morbidity of the disease[17]. Therefore, it is important 
to monitor membrane fusion and stem specific response not just in context of universal flu 
vaccine, but also to test the safety of vaccine that generates stem specific antibodies. 
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Summary Of Thesis: 
The functional assays currently used for measuring antibody response generated by 
influenza vaccine provide only fragmentary information about the mode of protection of the 
antibodies. For example, HI assay only measures titers in terms of blocking of attachment of 
virus to RBCs. MN assay cannot differentiate between blocking of attachment and blocking of 
membrane fusion by neutralizing antibodies. The aim of this project was to develop an assay that 
can assess functional characteristics and mechanisms of protection provided by influenza vaccine 
generated antibodies, i.e. blocking of virus attachment to the cells (pre-attachment  neutralization 
pathway) and blocking  fusion of viral membrane in the cell endosomes (major element of post-
attachment neutralization).  
Influenza virus attaches to its target cells by binding through globular head of HA trimer on its 
surface to the Sialic acid receptors present on glycolipids or glycoproteins of cellular 
membranes. Once the virus is attached to target cells, it gets internalized into endosomes due to 
cycling of cellular membranes. In the endosomes, the acidic environment splits apart the HA 
trimer, opening up the globular head and exposing the stem region. The stem region of the 
protein then turns itself inside out and exposes its hidden fusion peptide at its N terminus. Fusion 
peptide then inserts itself into endosomal membrane, bringing endosomal membrane and viral 
membrane closer together and fuse. The fusion of two membranes leads to stalk pore formation 
and release of viral RNA in cellular cytoplasm through the pore[18]. fMF assay monitors the 
process of virus attachment to the cells and endosomal membrane fusion by kinetically following 
interaction of target cells (vero cells) with Octadecyl Rhodamine B Chloride (R18) dye labeled 
Influenza virus. 
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Use of R18 dequenching for studying kinetics of fusion between biological membranes 
was first described by Hoekstra, D. et al in 1984[19]. Since then it has become a widely used 
label for studying fusion kinetics. R18 dye is lipophilic in nature; it enters the envelope of the 
virus and remains in the envelope in self quenched state. When the labeled virus fuses with 
another membrane such as host cell endosomal membrane, the dye gets diluted and becomes 
fluorescent. This increase in fluorescence due to dye dilution in membrane is indicative of viral 
endosomal membrane fusion[20]. 
The ability of fMF assay to monitor membrane fusion was tested using Bafilomycin a1 a 
specific endosomal acidification inhibitor. As Influenza needs acidic environment for membrane 
fusion to occur, the inhibitor blocked membrane fusion by 85%. Specificity of the assay was 
tested using two different subtypes viruses H1N1 (A/Puerto Rico/8/1934 and 
A/Brisbane/59/2007), and H3N2 virus (A/Aichi/68) with their respective subtype specific stem 
specific monoclonal antibodies. As stem region on HA is key participant in membrane fusion, 
stem specific mAbs effectively blocked membrane fusion. In addition, only subtype specific 
mAbs were able to block membrane fusion. There was no cross neutralization between different 
subtypes and their mAbs. In order to study effect of antibodies on attachment of virus, one H1N1 
head specific mAb was also included in the study. The head specific antibody blocked both 
attachment of the virus and membrane fusion. The study was concluded by testing pre- and post- 
sera from 2009 seasonal Influenza vaccination. The sera showed characteristics similar to head 
specific antibodies, at lower sera dilution (higher Ab concentration) majority of virus (85%) was 
blocked from attaching cells, but at higher sera dilution (lower Ab concentration) where 
attachment could not be prevented, blocking of membrane fusion was still in effect - up to 50%.  
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In conclusion fMF assay is a method that is able to monitor interaction of influenza virus and its 
target cells in a biomimetic manner. It is an assay that can functionally characterize response of 
post vaccination sera into two major neutralization pathways: blocking of attachment of virus 
and blocking of viral endosomal membrane fusion. By monitoring both the pathways in the same 
run the assay is able to demonstrate the interplay of these two neutralization pathways in 
presence of antibodies. With conventional assays only being able to either monitor blocking of 
attachment or altogether neutralization, fMF assay opens the door for monitoring an important 
new correlate of protection, the membrane fusion. Monitoring membrane fusion is very 
important in context of universal flu vaccine and pandemic threats. 
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METHODOLOGY 
Labeling Influenza Virus 
Influenza viruses PR8 (A/Puerto Rico/8/1934 H1N1), X-31(A/Aichi/68 H3N2) (Charles 
River laboratory) and Brisbane H1N1 (A/Brisbane/59/2007 H1N1) (Sanofi Pasteur) were labeled 
with Octadecyl Rhodamine B chloride dye (R18) (Life Technologies). Viral protein content was 
determined using BCA kit (Pierce Technology) using high grade Bovine Serum Albumin (BSA; 
Sigma-Aldrich) as internal standard. 100µg of viral protein was labeled with 5µg R18 while 
vortexing. Labeled virus was then incubated at room temperature for one hour on orbital shaker. 
The labeled virus was stored at 4ºC. The virus was used within one week after labeling. 
Vero Cell Culture 
Vero cells were obtained from ATCC, USA. Cells were grown in Iscove’s Modified 
Dulbecco’s Medium (IMDM, ATCC) containing 4mM L-glutamine, 4500mg/L glucose and 
1500mg/L sodium bicarbonate with fetal bovine serum (10%) and 1% penicillin-streptomycin-
glutamine (Life Technologies). Cells were maintained at 37ºC, 5% CO2 in a humidified 
incubator.  
Fluorescent Membrane Fusion Assay 
1µg of labeled virus was incubated with 500,000 vero cells on ice in BSA buffer ,1% 
Bovine serum albumin (Sigma-Aldrich) in Dulbecco phosphate buffered saline (DPBS) (Lonza) 
for 45 minutes. The cells with virus were then washed two times with cold BSA buffer. The cells 
were then resuspended in BSA buffer pre-warmed at 37ºC. The kinetics of interaction of virus 
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with the cells was then read on ELISA plate reader (Biotek instruments) in fluorescence mode. 
The excitation wavelength of 530 nm was used and emission at 590 nm was observed. The 
kinetic study was carried out for 30 minutes with an interval of 10 to 20 seconds. At the end of 
kinetics study, 10µl of 10% Triton X (Invitrogen) was added to cells and fluorescence generated 
after addition of Triton X was recorded. 
In order to assess the ability of fMF assay to monitor endosomal fusion, an endosomal 
acidification inhibitor Bafilomycin a1 (Sigma Aldrich) was used. For the experiments carried out 
in presence of Bafilomycin a1, the BSA buffer in fMF assay was replaced with a 100 nM 
solution of Bafilomycin a1 prepared in BSA buffer. 
In order to assess the subtype specificity of fMF assay, a group of subtype specific mAbs 
were tested in the fMF assay. Table 1 shows the list of all the antibodies used in this study. 
For the experiments carried out in presence of monoclonal antibodies (mAbs), the virus 
was incubated overnight at 4°C with the mAbs diluted at appropriate concentration in BSA 
buffer. The viruses preincubated with mAbs were then incubated with cells and the fMF assay 
was carried out in the same way as described above.  
Table 1: List of monoclonal antibodies 
mAb Epitope specificity Source 
M145 
H1N1 stem 
Takara Bio Inc 
Aca-1 
Sanofi Pasteur  
Cambridge Campus 
Aca-2 
Aca-3 H3N2 stem 
Aca-4 H1N1 head 
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Pre and post vaccination sera obtained from human donors who received 2008 influenza 
vaccine were analyzed using fMF assay. The donor sera were diluted appropriately in BSA 
buffer. The viruses were preincubated with diluted sera for one hour at 4°C. The viruses were 
then incubated with cells and the fMF assay was carried out in the same way as described above. 
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RESULTS 
Scheme Of Study 
The study was divided into five stages, and their deliverables are described below. Figure 
1 shows the breakdown of these stages. 
Stage 1: Show that the presence of endosomal acidification blocker blocks membrane fusion. 
Stage 2: Test the effect of presence of stem specific mAbs on membrane fusion. Demonstrate 
the specificity of fMF assay by testing two different subtypes of viruses PR8 H1N1 and X-31 
H3N2 with their subtype specific mAbs. 
Stage 3: Transition to a vaccine strain influenza virus, Brisbane H1N1. Use fMF assay to study 
blocking of membrane fusion of Brisbane H1N1 virus in presence of stem specific antibodies 
Stage 4:  Use fMF assay to study blocking of attachment of Brisbane H1N1 virus in presence of 
head specific antibodies 
Stage 5:  Use fMF assay to study effect of presence of pre and post vaccination on attachment 
and membrane fusion of Brisbane H1N1 virus. 
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Figure 1 Scheme of study 
Effect of Blocking Membrane Fusion on fMF Read Out 
In order to assess whether fMF assay that is based on dequenching of R18 fluorescent 
probe can monitor endosomal processing of influenza virus, an endosomal acidification blocker 
Bafilomycin a1 was used. Bafilomycin a1 is an H+ VATPases blocker. V-ATPase is a proton 
pump which is responsible for pumping protons into endosomes and acidifying the endosomal 
compartments. 
For fusing with endosomal membrane, the influenza, virus needs presence of acidic 
environment in the endosomes. Therefore, presence of bafilomycin a1 should have a blocking 
effect on membrane fusion. 
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Figure 2 Endosome acidification inhibitor blocks R18 dequenching 
A: R18 dequenching %, relative to total fluorescence. 
B: Fusion at 20 minutes, relative to No Treatment. 
C: Total virus attachment relative to No Treatment, determined by measuring total 
fluorescence after adding detergent that disperses membranes and releases the dye. 
Figure 2 shows that in comparison to no treatment, using endosomal acidification blocker 
Bafilomycin A1 reduced the relative fusion by ~ 85% without affecting attachment of virus 
to cells. This shows that the dequenching of R18 observed in our experiments is indicative of 
endosomal fusion of influenza virus. We also observed a lag of ~ 7 minutes before the 
beginning of dequenching, this lag possibly corresponds to endocytosis of virus by the cells. 
This experiment was a first step to show that the fMF assay that uses R18 dequenching can 
address influenza virus endocytosis and endosomal fusion. 
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Effect Of Stem Specific Antibodies on Membrane Fusion Of Two Different Subtypes Of 
Influenza Viruses 
In order to prove that fMF assay can represent endosomal membrane fusion, stem 
specific mAbs were used to test the system. Since stem region of hemagglutinin plays an 
important role in the membrane fusion process, stem specific antibodies should block membrane 
fusion. 
Two viruses belonging to two different subtypes, PR8 (H1N1) and X-31 (H3N2) were 
tested with subtype specific stem related mAbs in order to to demonstrate the ability of fMF 
assay to differentiate between different subtypes of viruses and their respective antibodies. 
 
Figure 3 H1N1 specific mAb M145 blocks fusion of PR8 (H1N1) virus 
Figure 3 shows effect of stem specific murine mAb M145 on membrane fusion and 
attachment of PR8 virus. M145 is known to be a H1N1 stem specific mAb and it blocked fusion 
of a H1N1 virus. 50% titer for M145 with PR8 virus was 2.6 µg/ml. M145 blocked fusion of the 
virus without affecting its attachment to vero cells. Stem region of the HA plays important role 
in fusion of viral and endosomal membranes. Blocking of fusion in presence of stem specific 
mAb shows that fMF assay is indicative of endosomal fusion process. In most of the following 
experiments, M145 was used as a positive control at 10 mg/ml. 
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Figure 4 H1N1 specific mAbs Aca-1 and Aca-2 block fusion of PR8 (H1N1) virus 
A and B: Effect of mAb Aca-1 on blocking membrane fusion and attachment of PR8 virus. 
C and D: Effect of mAb Aca-2 on blocking membrane fusion and attachment of PR8 virus. 
Figure 4 shows effect of human derived mAbs Aca-1 and Aca-2 on membrane fusion and 
attachment of PR8 virus. Both antibodies blocked membrane fusion in dose dependent manner 
without affecting the attachment of virus to vero cells. Aca-1 and Aca-2 are H1N1 stem region 
specific mAbs, their blocking of membrane fusion of an H1N1 virus without affecting its 
attachments shows that fMF assay is able to observe endosomal membrane fusion in fMF assay. 
The 50% titer of the Aca-1 and Aca-2 mAb’s were 0.2 and 0.5 µg/ml respectively. 
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Figure 5 H3N2 specific mAb Aca-3 does not block fusion of PR8 (H1N1) virus 
 
Figure 6 H3N2 specific mAb Aca-3 blocks fusion of X-31 (H3N2) virus 
Figure 5 shows that an H3N2 stem specific mAb Aca-3 does not block membrane fusion 
of PR8, an H1N1 virus. The experiment was carried out to demonstrate the specificity of fMF 
assay. The membrane fusion of H1N1 virus can only be blocked by a H1N1 specific mAb, not 
with a H3N2 specific mAb. 
Figure 6 shows that Aca-3 which is a H3N2 stem specific mAb blocks membrane fusion 
of X-31 H3N2 virus in dose dependent manner. This corroborates the capacity of fMF assay to 
differentiate between H1N1 and H3N2 specific antibodies and between corresponding viruses. 
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At 20 µg/ml Aca-3 showed a slight and possibly nonspecific effect on attachment as well, this 
could be due to high Ab concentration. 
 
Figure 7 H1N1 specific mAbs do not block fusion of X-31 (H3N2) virus 
A and B: Effect of mAb M145 on blocking membrane fusion and attachment of X-31 virus. 
C and D: Effect of mAb Aca-1 on blocking membrane fusion and attachment of X-31 virus 
E and F: Effect of mAb Aca-2 on blocking membrane fusion and attachment of X-31 virus 
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Figure 7 shows the effect of H1N1 stem specific antibodies on membrane fusion and 
attachment of X-31 H3N2 virus. H1N1 stem specific mAbs M145, Aca-1 and Aca-2 were not 
able to block membrane fusion and attachment of X-31 virus to vero cells. This set of 
experiments served as negative control for H3N2 subtype of virus and were carried to 
demonstrate specificity of fMF assay. 
The series of experiments with mAbs showed that membrane fusion can be blocked by 
stem specific mAbs. This further supported capacity of fMF assay to monitor membrane fusion 
and its blocking. The subtype specific antibodies showed that fusion of influenza viruses of two 
different subtypes (PR8 and X-31) could only be blocked by mAbs specific to their serotypes. 
These results show that fMF assay is very specific and able to differentiate between two very 
distinct subtypes of influenza viruses. 
Applicability Of fMF Assay To A Seasonal Influenza Strain A/Brisbane/59/2007 H1N1 
In order to achieve the main objective of this project “Use fMF assay to test vaccine 
generated Abs in biomimetic manner”, a more recent vaccine strain Brisbane H1N1 was tested in 
the fMF experiments. 
Table 2 Summary of the fMF assay titers using Brisbane H1N1 virus and stem specific mAbs 
mAb Epitope specificity Titer µg/ml 
Aca-1 
H1N1 stem 
1.25 
Aca-2 1.25 
Aca-3 H3N2 stem 
Subtype mismatch hence does 
not block fusion of H1N1 
virus 
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Aca-1, Aca-2 and Aca-3 were used to test applicability of fMF assay to Brisbane H1N1 
virus. Table 2 shows the summary of results from dose titration experiments of mAbs with 
Brisbane H1N1 virus. H1N1 stem specific mAbs Aca-1 and Aca-2 were able to block fusion of 
Brisbane H1N1 virus. Aca-3 which is H3N2 specific mAb did not have an effect on the fusion of 
Brisbane H1N1 virus. This shows that vaccine specific strain Brisbane H1N1 virus performed 
well in fMF assay. 
An H1N1 head specific mAb Aca-4 was used in order to test the capacity of fMF assay to 
monitor blocking virus attachment. Brisbane H1N1 virus was incubated with different dilutions 
of Aca-4 and the effect of presence of Aca-4 antibody on virus attachment and membrane fusion 
was monitored. 
 
Figure 8 Effect of head specific mAb Aca-4 on attachment and membrane fusion of Brisbane 
H1N1 virus 
Figure 8 shows that at a higher antibody concentration 1µg/ml head specific mAb Aca-4 
blocks attachment of the virus to cells by 85%. For the remaining 15% of the attached virus, 70% 
of fusion is blocked. Fusion % for each condition was calculated using total fluorescence 
generated by virus attached at that condition. Therefore, at 1 µg/ml, fusion blocking was 
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calculated using fluorescence corresponding to ~15% virus attached. At a lower antibody 
concentration 0.25 µg/ml, 50% fusion was blocked and there was no effect on attachment of 
virus to the cells. 
Blocking of fusion in presence of head specific mAb was an unexpected outcome. 
However, there are some previous studies that have shown that head specific mAbs have 
membrane fusion blocking effect[21, 22]. These studies have shown that mAbs directed towards 
different antigenic sites on HA head are capable of post attachment neutralization and this post 
attachment neutralization is accomplished by blocking membrane fusion. 
Presence of head specific antibody Aca-4 blocked attachment of virus and membrane 
fusion. fMF assay was able to detect both effects in a single run. Therefore, the assay was turned 
to study effects on attachment and fusion of Brisbane H1N1 virus in presence of sera from 
vaccinated donors. 
FMF Assay To Monitor Blocking Of Fusion and Attachment Of Influenza Virus By Vaccine 
Generated Antibodies In Donor Sera 
The objective of this set of experiments was to test ability of fMF assay to screen pre- 
and post-vaccination human sera for their capacity to block fusion and attachment, in a single 
run. Pre- and post-vaccination sera of four human donors immunized with 2009 seasonal flu 
vaccine was run through the fusion assay using Brisbane H1N1 virus. This strain of virus was 
used since 2009 seasonal flu vaccine contained Brisbane H1N1 virus antigen.  
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Figure 9 Monitoring the capacity of pre and post vaccination sera to block attachment and fusion 
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Figure 9 shows fMF assay data from four donors. Pre and post vaccination sera from four 
human donors were run through fMF assay. Donor #1142 and donor #981 were high responders, 
the other two donors, #654 and #821 were low responders. High responder sera showed blocking 
profile similar to head specific mAb Aca-4. At higher sera concentration, 80-50% virus was 
blocked from attaching cells. For the remaining attached 20-50% of the virus, fusion was 
blocked by 50-80%. At lower sera concentration, when blocking of attachment was no longer 
effective, blocking of fusion was still in effect up to 50%. A low responder post vaccination 
serum, donor #821, showed insignificant capability of blocking of virus attachment. On the other 
hand, the same donor showed an effective 50% blocking of membrane fusion. The blocking of 
membrane fusion in the absence of blocking of attachment shows the value of fMF assay. The 
donors which appear to be nonresponder in attachment blocking tests such as HAI can show 
response in a post attachment step such as blocking membrane fusion. 
 
Figure 10 Correlation of fMF assay titers and HAI titers 
Titers from fMF assay were compared with titers from classical HAI assay. Figure 10 
shows that blocking of attachment and membrane fusion observed in the fMF assay positively 
correlated with the data of classical HAI assay. 
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In the same time, blocking of membrane fusion has been observed for a serum which 
showed insignificant capacity to block attachment (#821), which may signify importance of 
neutralization via membrane fusion blocking pathway. 
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DISCUSSION 
fMF assay was developed to meet two unmet needs of influenza vaccine assessment, first 
to assess a new correlate of protection of influenza vaccine i.e. the stem specific response and 
second to simultaneously analyze immune sera for pre attachment neutralizing and post 
attachment neutralization antibodies. The method ties together the two major neutralization 
pathways: blocking attachment of virus to host cells and blocking of membrane fusion of the 
internalized virus in the endosomes. 
fMF assay was tested for its ability to monitor membrane fusion by using Bafilomycin 
a1, a very specific endosomal acidification blocker. By demonstrating that Bafilomycin a1blocks 
85% of membrane fusion without affecting the attachment of virus, the fMF assay was shown to 
be representative of endosomal fusion process. The specificity of the assay and its capacity to 
measure stem specific response was tested by using subtype specific stem related antibodies. It 
was shown by using two subtypes of viruses H1N1 and H3N2 and their respective stem specific 
antibodies, that fMF assay is able to monitor blocking of membrane fusion in presence of stem 
specific antibodies. The assay is also able to distinguish between two distinct subtypes of viruses 
H1N1 and H3N2, as their membrane fusion was blocked only in presence of their subtype 
specific antibodies. Experiments with stem specific antibodies further corroborated the capacity 
of fMF assay to measure stem specific response and the subtype specificity of the assay. 
A head specific mAb was used to study its effect on attachment and fusion of Brisbane 
H1N1 virus. Expected outcome of this experiment was that head specific mAb should block 
attachment of Brisbane H1N1 virus and fusion should remain unaffected. On the contrary, the 
head specific antibody not only blocked attachment of virus, it also had a significant effect on 
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blocking membrane fusion. Similar results with head specific antibodies have been observed in 
some previous studies where they have shown that head specific mAbs neutralize influenza virus 
by preferentially blocking attachment of virus. However, when at 50% neutralization the 
blocking of virus attachment was minimal. Therefore, there was some other mechanism that 
blocked infectivity of virus. It was shown in the same study that there is a very strong correlation 
between infectivity and membrane fusion. Therefore, it was proposed that head specific 
antibodies along with blocking attachment can also block membrane fusion by either sterically 
interfering with fusion process or by crosslinking two adjacent HA trimers[21]. 
After substantiating fMF assay with mAbs, sera screening experiments were performed. 
fMF assay was able to detect blocking of both fusion and attachment in the presence of immune 
sera in a single run. The high responder sera showed characteristics similar to a head specific 
mAb. At higher sera concentration, blocking of attachment was most effective, i.e 85% of virus 
was prohibited from attaching the cells. At lower sera concentration when blocking of 
attachment was not effective, the sera were still able to block post attachment membrane fusion 
of virus. Sera screening experiments showed that sera antibodies work beyond just blocking 
attachment. They may also neutralize the already attached virus by blocking fusion of the viral 
membrane in the endosomes. This could mean that in order to achieve protection from influenza, 
lesser quantity of antibodies may be needed than what can be required based on HAI data alone. 
Therefore, for in vitro vaccine testing, blocking of membrane fusion needs to be taken into 
consideration as a very important neutralization pathway. 
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The assay has demonstrated ability to monitor blocking of attachment and fusion in a 
single run. Therefore, it is more representative regarding the natural process of infection and the 
corresponding neutralization pathways.  
For future applications, fMF assay can be developed for other enveloped viruses, such as 
dengue and filoviruses to study the neutralization pathways and functional characteristics of 
antibodies generated by vaccine candidates. Other cell types other, such as monocytes, dendritic 
cells or NK cells can also be used in fMF assay to study effect of antibodies on protection of 
different types of target cells. 
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